HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effects of olanzapine-fluoxetine combination treatment of major depressive disorders on the quality of life during acute treatment period.

Abstract
The objective of the study was to explore the effects of olanzapine-fluoxetine combination (OFC) treatment of major depressive disorders on the quality of life in the acute treatment period. Methods were prospective and observational design. One hundred and three patients of major depressive disorders were observed. One group of 53 patients received OFC treatment (OFC group); the other group of 50 patients received the treatment of duloxetine (duloxetine group). Two groups were needed to be observed 8 weeks. Observed indicators were Hamilton Depression Rating Scale for Depression (HAMD-24) and four factor scores: the slow, sleep disorders, anxiety/somatization, and hopelessness, Clinical Global Impression-Severity of Illness (CGI-S), WHO quality of life scale (WHOQOL-BREF), and sub-rate measurements. HAMD-24 and four factor scores observation time were assessed before and after treatment; 1, 2, 4, 8 weeks, WHOQOL-BREF score, and sub-time measurements were assessed before treatment and 8 weeks after treatment. HAMD-24 scores of OFC patients in the first week were significantly lower than those of the duloxetine group. The sleep factor scores of OFC patients were significantly lower than those of the duloxetine group in 4 and 8 weeks. By the end of 8 weeks, OFC group was rated significantly lower than the duloxetine group in the physical area. In the acute treatment period, OFC treatment effected faster than the single duloxetine in patients with major depressive disorders. OFC effected within 1 week and was better than the single duloxetine in improving the sleep and physical conditions.
AuthorsWei Qu, Shanshan Gu, Han Luo, Qianying Tang, Junwei Guo
JournalCell biochemistry and biophysics (Cell Biochem Biophys) Vol. 70 Issue 3 Pg. 1799-802 (Dec 2014) ISSN: 1559-0283 [Electronic] United States
PMID25062968 (Publication Type: Clinical Trial, Comparative Study, Journal Article)
Chemical References
  • Drug Combinations
  • Thiophenes
  • olanzapine-fluoxetine combination
  • Fluoxetine
  • Benzodiazepines
  • Duloxetine Hydrochloride
Topics
  • Adult
  • Benzodiazepines (adverse effects, therapeutic use)
  • Depressive Disorder, Major (drug therapy, psychology)
  • Drug Administration Schedule
  • Drug Combinations
  • Duloxetine Hydrochloride
  • Female
  • Fluoxetine (adverse effects, therapeutic use)
  • Humans
  • Male
  • Middle Aged
  • Psychiatric Status Rating Scales
  • Quality of Life
  • Sleep Wake Disorders (etiology)
  • Somatoform Disorders (etiology)
  • Thiophenes (adverse effects, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: